This post by IRMA’s Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance. The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out Read More >>

[Click here for the VOICE press release – “Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study” – from the Microbcide Trials Network] IRMA, like the rest of new prevention technology researchers and advocates, is disappointed to learn that daily oral Truvada was not found to be an effective HIV intervention among the African women at Read More >>

via Lancet.com, by Salim S Abdool Karim  and Quarraisha Abdool Karim On May 10, 2012, a US Food and Drug Administration (FDA) advisory committee voted in support of the use of tenofovir-emtricitabine for HIV prevention.1 If the FDA, which is scheduled to make its decision by June 15, adopts the committee’s recommendations, tenofovir-emtricitabine will become the first Read More >>

viaAllAfrica, interview with Professor Salim Abdool Karim Professor Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa (Caprisa) at the University of KwaZulu-Natal and Columbia University in the United States, spoke to AllAfrica’s Julie Frederikse about the unexpected halt of a study into tenofovir vaginal gel. This followed a finding Read More >>

via allAfrica.com, by Julie Frederikse Africans tracking the worldwide HIV epidemic have not found much to celebrate since Aids began ravaging the continent 30 years ago, but researchers are optimistic that they are learning as much from their failures as their successes. Sub-Saharan Africa still carries the biggest burden of HIV worldwide, and while there has been Read More >>

25 November, 2011IRMA Expresses Disappointment; Calls for MTN 017 to Move Forward International Rectal Microbicide Advocates (IRMA) expresses disappointment regarding today’s announcement that the vaginal tenofovir gel arm in the Microbicide Trial Network’s (MTN) VOICE trial is being discontinued. VOICE has been exploring two ARV-based HIV prevention approaches since it began enrolling women in high incidence areas Read More >>